Germany Biochip Market, 2026-2033
Germany Biochip Market, 2021-2033 (US$M)
Global Market
Related Markets
Germany biochip market highlights
- The Germany biochip market generated a revenue of USD 1,237.3 million in 2025 and is expected to reach USD 2,976.1 million by 2033.
- The Germany market is expected to grow at a CAGR of 11.2% from 2026 to 2033.
- In terms of segment, dna chips was the largest revenue generating type in 2025.
- Lab-on-chip is the most lucrative type segment registering the fastest growth during the forecast period.
Biochip market data book summary
| Market revenue in 2025 | USD 1,237.3 million |
| Market revenue in 2033 | USD 2,976.1 million |
| Growth rate | 11.2% (CAGR from 2026 to 2033) |
| Largest segment | Dna chips |
| Fastest growing segment | Lab-on-chip |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | DNA Chips, Lab-on-chip, Tissue Arrays, Protein Chips, Cell Arrays |
| Key market players worldwide | Agilent Technologies Inc, PerkinElmer, Illumina Inc, Bio-Rad Laboratories Inc, Standard BioTools Inc, GE HealthCare Technologies Inc Common Stock, Thermo Fisher Scientific Inc, Qiagen NV, Randox |
Other key industry trends
- In terms of revenue, Germany accounted for 8.1% of the global biochip market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, UK biochip market is projected to lead the regional market in terms of revenue in 2033.
- UK is the fastest growing regional market in Europe and is projected to reach USD 2,995.3 million by 2033.
According to the Robert Koch Institute, around 502,655 people were diagnosed with cancer in 2019. Thus, the high burden of cancer and the growing need for rapid diagnostics are anticipated to support the global biochip market.
An in-depth analysis of the genome of cancerous cells is important for optimal understanding of diseases to advance treatment. Hence, the German Cancer Consortium, in association with German Cancer Research, invested in the Illumina HiSeq X sequencing solution in 2015.
With the ability to sequence more than 18,000 genomes annually, it is the first and most innovative technology in the world to provide complete coverage of the entire human genome for under EUR 1,000 per genome.
No credit card required*
Publish Date: Jun 17, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Biochips Market
Biochips Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| GE HealthCare Technologies Inc Common Stock | View profile | 51,000 | 500 West Monroe Street, Chicago, IL, United States, 60661 | www.gehealthcare.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Agilent Technologies Inc | View profile | 17,700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | www.agilent.com |
| Bio-Rad Laboratories Inc | View profile | 8,030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | www.bio-rad.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Standard BioTools Inc | View profile | 539 | 2 Tower Place, Suite 2000, South San Francisco, CA, United States, 94080 | www.standardbio.com |
| PerkinElmer | View profile | 10001+ | Waltham, Massachusetts, United States, North America | www.perkinelmer.com |
| Randox | View profile | 1001-5000 | Crumlin, Antrim, United Kingdom, Europe | www.randox.com |
Germany biochips market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Biochip Market will help companies and investors design strategic landscapes.
Dna Chips was the largest segment with a revenue share of 42.87% in 2025.
Horizon Databook has segmented the Germany biochip market based on dna chips, lab-on-chip, tissue arrays, protein chips, cell arrays covering the revenue growth of each sub-segment from 2021 to 2033.
According to the Robert Koch Institute, around 502,655 people were diagnosed with cancer in 2019. Thus, the high burden of cancer and the growing need for rapid diagnostics are anticipated to support the global biochip market.
An in-depth analysis of the genome of cancerous cells is important for optimal understanding of diseases to advance treatment. Hence, the German Cancer Consortium, in association with German Cancer Research, invested in the Illumina HiSeq X sequencing solution in 2015.
With the ability to sequence more than 18,000 genomes annually, it is the first and most innovative technology in the world to provide complete coverage of the entire human genome for under EUR 1,000 per genome.
- Germany Biochip Market Type Outlook (Revenue, USD Million , 2021-2033)
- DNA Chips
- Protein Chips
- Lab-on-chip
- Tissue Arrays
- Cell Arrays
- Germany Biochip Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Biotechnology and Pharmaceutical Companies
- Hospitals and Diagnostics Centers
- Academic & Research Institutes
- Others
Reasons to subscribe to biochips market databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of biochips market databook
- Our clientele includes a mix of biochips market companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany biochips market, including forecasts for subscribers. This country databook contains high-level insights into Germany biochips market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Germany Biochip Market, 2021-2033 (US$M)
Germany Type - Biochip Market, 2025 - 2033 (US$M)
